DUBLIN — April 2, 2020 — Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held development-stage biopharma company, and its development-stage oral...
TargeGen successfully completed enrollment of a multi-center clinical trial of TG101348
News | 05. 14. 2009
TargeGen
SAN DIEGO, May 14, 2009 /PRNewswire/ — TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis on May 7, 2009.
